SEC Filing Summary: BioSig Technologies, Inc.
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. (not Streamex Corp.) on March 21, 2017, reporting events occurring on March 15, 2017. The filing details a strategic partnership with the Mayo Foundation for Medical Education and Research.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial terms disclosed relate to a specific transaction:
- Warrant Issuance: A three-year cash warrant to purchase 630,000 shares of common stock.
- Exercise Price: $1.50 per share.
- Future Obligations: Agreement to pay earned royalty payments on sales of Licensed Products to third parties.
Material Changes
The primary material change is the entry into a Material Definitive Agreement (Item 1.01) and the unregistered sale of equity securities (Item 3.02). The Company secured a non-exclusive license for research data and an exclusive license to develop, make, sell, and import specific "Licensed Products" from Mayo. In exchange, the Company issued the aforementioned warrant and committed to future royalty payments.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future performance. The primary risk disclosed is the dilution of existing shareholders due to the issuance of 630,000 warrant shares and the future cash outflow associated with royalty payments contingent on product sales.
Investor Verification Checklist
- Verify the specific scope and definition of the "Licensed Products" within the full agreement text.
- Confirm the exact terms of the royalty payment structure (e.g., percentage of sales, tiered rates).
- Assess the potential dilution impact of the 630,000 warrants on current share count.
- Review the Company's cash position to ensure it can meet future royalty obligations if sales materialize.